Parkinson’s Disease and Behavioral Complications – PD Therapies Dominate First-In-Class Pipeline, With Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Parkinson’s disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated dementia and PD-associated psychosis are both highly prevalent and associated with a large disease burden.
There is a pressing unmet need within PD, PD-associated dementia, and PD-associated psychosis for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relief, there are no commercially available agents capable of preventing or slowing the course of PD or its behavioral complications. This report assesses innovation within the pipeline for PD and its behavioral complications.


The PD pipeline is large, with 456 programs in active development. Far fewer products are in development for the behavioral complications of PD. There are 16 products in development for PD-associated dementia and six products in development for PD-associated psychosis. What proportion of these products across PD and PD behavioral complications are first in class? How does first-in-class innovation vary by development stage and molecular target class?

Innovative molecular target groups identified in the pipeline include immunomodulators, neuroprotectants, and protein misfolding and aggregation. Which molecular target classes are prominently represented in the overall and first-in-class pipelines for PD and PD behavioral complications?

There are 351 companies active across PD and PD behavioral complications. Which companies have the most first-in-class assets in development? Which companies are highly active in terms of licensing and co-development deals for first-in-class innovation?

Reasons to Buy

Understand the current disease landscape with an in-depth discussion of etiology, pathophysiology, disease classification and staging systems, epidemiology, and marketed therapies for PD. Overviews of PD-associated dementia and PD-associated psychosis are also provided.

Analyze the pipelines for PD, PD-associated dementia, and PD-associated psychosis, and stratify them by stage of development, molecule type, and molecular target.

Assess the therapeutic potential of first-in-class molecular targets. Using proprietary matrix assessments, first-in-class molecular targets for PD and PD-associated dementia have been assessed and ranked according to clinical potential. A matrix assessment is not provided for PD-associated psychosis due to a lack of first-in-class innovation. Promising first-in-class targets for PD and PD-associated dementia have been reviewed in greater detail.

Analyze company strategies in prior deals through case studies of key deals for PD first-in-class products, and recognize commercial opportunities by identifying first-in-class pipeline products that have not yet been involved in licensing or co-development deals.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Parkinson’s Disease and Behavioral Complications: Executive Summary

2.1 High Unmet Need Remains for Disease-Modifying Pharmacotherapies

2.2 Large and Innovative Parkinson’s Disease Pipeline Indicates Shift Towards Disease-Modifying Approaches

2.3 Novel Gene Therapies Attract High Levels of Investment in Parkinson’s Disease

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

4.3 Sustained Innovation in Parkinson’s Disease

4.4 Epidemiology for Parkinson’s Disease

4.5 Overview for Marketed Products

4.6 Overview for Behavioral Complications in Parkinson’s Disease

4.6.1 Overview of Parkinson’s Disease-Associated Dementia

4.6.2 Overview of Parkinson’s Disease-Associated Psychosis

5 Assessment of Pipeline Product Innovation

5.1 Overview

5.2 Pipeline by Stage of Development and Molecule Type

5.3 Pipeline by Molecular Target

5.4 Comparative Distribution of Programs Between the Parkinson’s Disease Market and Pipeline by Therapeutic Target Family

5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class

5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs

5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Targets Within the Pipeline

6 First-in-Class Molecular Target Evaluation

6.1 Overview

6.2 Pipeline Programs Targeting [Identified Target #1]

6.3 Pipeline Programs Targeting [Identified Target #2]

6.4 Pipeline Programs Targeting [Identified Target #3]

6.5 Pipeline Programs Targeting [Identified Target #4]

6.6 Pipeline Programs Targeting [Identified Target #5]

6.7 Pipeline Programs Targeting [Identified Target #6]

6.8 Pipeline Programs Targeting [Identified Target #7]

6.9 Pipeline Programs Targeting [Identified Target #8]

7 Key Players and Deals

7.1 Overview

7.1.1 AbbVie and Voyager Therapeutics Enter into Co-development Agreement

7.1.2 Axovant Sciences Enters into Licensing Agreement with Oxford Biomedica

7.1.3 Pfizer Enters into Licensing Agreement with Arvinas

8 Appendix

8.1 Bibliography

8.2 Abbreviations

8.3 Methodology

8.4 About the Authors

8.4.1 Analyst

8.4.2 Therapy Area Director

8.4.3 Global Director of Therapy Analysis and Epidemiology

8.4.4 Global Head and EVP of Healthcare Operations and Strategy

8.5 About GlobalData

8.6 Contact Us

8.7 Disclaimer

Frequently asked questions

Parkinson’s Disease and Behavioral Complications – PD Therapies Dominate First-In-Class Pipeline, With Novel Target Classes Demonstrating Potential Disease-Modifying Effects thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Parkinson’s Disease and Behavioral Complications – PD Therapies Dominate First-In-Class Pipeline, With Novel Target Classes Demonstrating Potential Disease-Modifying Effects was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Synthetic Biology - Thematic Intelligence
$995 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Parkinson’s Disease and Behavioral Complications – PD Therapies Dominate First-In-Class Pipeline, With Novel Target Classes Demonstrating Potential Disease-Modifying Effects in real time.

  • Access a live Parkinson’s Disease and Behavioral Complications – PD Therapies Dominate First-In-Class Pipeline, With Novel Target Classes Demonstrating Potential Disease-Modifying Effects dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.